Skip to main content
SpringerLink
Log in

Chemosensitized radiosurgery for recurrent brain metastases

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Temozolomide is known to penetrate the blood–brain barrier and sensitize brain tumors to radiation and has been used clinically to sensitize fractionated external beam radiotherapy. However, there are limited prospective clinical data available on the safety of temozolomide as a chemosensitizing agent administered with stereotactic radiosurgery. This is a phase I trial of previously irradiated patients with one to four progressive brain metastases and Karnofsky performance scale score ≥60 % enrolled in three sequential cohorts: temozolomide 100, 150 or 200 mg/(m2 day) administered for 5 days. Stereotactic radiosurgery (SRS) was administered on day 5. The SRS dose was dependent on target diameter: 15 Gy (31–40 mm), 18 Gy (21–30 mm) or 21 Gy (<20 mm). The primary endpoint was safety of increasing temozolomide doses. Secondary endpoints included local control and survival. 26 subjects were enrolled and 49 total metastatic lesions were treated. The median number of brain metastases was 1.5, with a median target diameter of 21 mm. The most common grade 1–2 adverse events irrespective of causality were vomiting (23 %), nausea (23 %), edema (12 %), seizure (8 %), psychosis (4 %) and thrombocytopenia (4 %). The frequency of nausea and vomiting did not appear to be dose-dependent. Grade 3–4 toxicities were not observed. Median overall survival was 10.2 months. Crude local control was 87.5 %, with a radiological response seen in eight of 24 evaluable patients (33.3 %), and stable disease >6 months in 13 of 24 patients (54.2 %). Temozolomide, at doses up to 200 mg/(m2 day) × 5 days, prior to SRS is well tolerated, with no dose-limiting toxicities in patients with recurrent brain metastases. Local control of target lesions was >80 %.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Easaw JC, Mason WP, Perry J et al (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 18:e126–e1362

    Article  PubMed  CAS  Google Scholar 

  2. Mason WP, Maestro RD, Eisenstat D et al (2007) Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol 14:110–117

    Article  PubMed  CAS  Google Scholar 

  3. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5 year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466

    Article  PubMed  CAS  Google Scholar 

  4. Bull VL, Tisdale MJ (1987) Antitumour imidazotetrazines––XVI. Macromolecular alkylation by 3-substituted imidazotetrazinones. Biochem Pharmacol 36:3215–3220

    Article  PubMed  CAS  Google Scholar 

  5. Pegg AE, Dolan ME, Moschel RC (1995) Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167–223

    Article  PubMed  CAS  Google Scholar 

  6. Geiger GA, Fu W, Kao GD (2008) Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system. Cancer Res 68:3396–3404

    Article  PubMed  CAS  Google Scholar 

  7. Kil WJ, Cerna D, Burgan WE et al (2008) In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 14:931–938

    Article  PubMed  CAS  Google Scholar 

  8. Tolcher AW, Gerson SL, Denis L et al (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004–1011

    Article  PubMed  CAS  Google Scholar 

  9. Addeo R, Caraglia M, Faiola V et al (2007) Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer 7:18

    Article  PubMed  Google Scholar 

  10. Addeo R, De Rosa C, Faiola V et al (2008) Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 113:2524–2531

    Article  PubMed  CAS  Google Scholar 

  11. Antonadou D, Paraskevaidis M, Sarris G et al (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644–3650

    Article  PubMed  CAS  Google Scholar 

  12. Atkins MB, Sosman JA, Agarwala S et al (2008) Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II cytokine working group study. Cancer 113:2139–2145

    Article  PubMed  CAS  Google Scholar 

  13. Chua D, Krzakowski M, Chouaid C et al (2010) Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. Clin Lung Cancer 11:176–181

    Article  PubMed  CAS  Google Scholar 

  14. Cortot AB, Geriniere L, Robinet G et al (2006) Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT–GFPC study. Ann Oncol 17:1412–1417

    Article  PubMed  CAS  Google Scholar 

  15. Giorgio CG, Giuffrida D, Pappalardo A et al (2005) Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung Cancer 50:247–254

    Article  PubMed  Google Scholar 

  16. Hofmann M, Kiecker F, Wurm R et al (2006) Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 76:59–64

    Article  PubMed  CAS  Google Scholar 

  17. Hwu WJ, Lis E, Menell JH et al (2005) Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103:2590–2597

    Article  PubMed  CAS  Google Scholar 

  18. Iwamoto FM, Omuro AM, Raizer JJ et al (2008) A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 87:85–90

    Article  PubMed  CAS  Google Scholar 

  19. Kouvaris JR, Miliadou A, Kouloulias VE et al (2007) Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie 30:361–366

    Article  PubMed  CAS  Google Scholar 

  20. Verger E, Gil M, Yaya R et al (2005) Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 61:185–191

    Article  PubMed  CAS  Google Scholar 

  21. Conti A, Pontoriero A, Arpa D et al (2012) Efficacy and toxicity of CyberKnife re-irradiation and “dose dense” temozolomide for recurrent gliomas. Acta Neurochir 154:203–209

    Article  Google Scholar 

  22. Balducci M, Apicella G, Manfrida S et al (2010) Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. Strahlenther Onkol 186:558–564

    Article  PubMed  Google Scholar 

  23. Bobola MS, Kolstoe DD, Blank A et al (2010) Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. Mol Cancer Ther 9:1208–1218

    Article  PubMed  CAS  Google Scholar 

  24. Chalmers AJ, Ruff EM, Martindale C et al (2009) Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. Int J Radiat Oncol Biol Phys 75:1511–1519

    Article  PubMed  CAS  Google Scholar 

  25. Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672

    Article  PubMed  Google Scholar 

  26. Shaw E, Scott C, Souhami L et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291–298

    Article  PubMed  CAS  Google Scholar 

  27. Dea N, Borduas M, Kenny B et al (2010) Safety and efficacy of Gamma Knife surgery for brain metastases in eloquent locations. J Neurosurg 113(Suppl):79–83

    PubMed  Google Scholar 

  28. Davey P, O’Brien PF, Schwartz ML et al (1994) A phase I/II study of salvage radiosurgery in the treatment of recurrent brain metastases. Br J Neurosurg 8:717–723

    Article  PubMed  CAS  Google Scholar 

  29. Hoffman R, Sneed PK, McDermott MW et al (2001) Radiosurgery for brain metastases from primary lung carcinoma. Cancer J 7:121–131

    PubMed  CAS  Google Scholar 

  30. Vogelbaum MA, Angelov L, Lee SY et al (2006) Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg 104:907–912

    Article  PubMed  Google Scholar 

  31. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    Article  PubMed  CAS  Google Scholar 

  32. Gonzalez-Gomez P, Bello MJ, Alonso ME et al (2004) Promoter methylation status of multiple genes in brain metastases of solid tumors. Int J Mol Med 13:93–98

    PubMed  CAS  Google Scholar 

  33. Ingold B, Schraml P, Heppner FL et al (2009) Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. PLoS ONE 4:e4775

    Article  PubMed  Google Scholar 

  34. Wu PF, Kuo KT, Kuo LT et al (2010) O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer 68:484–490

    Article  PubMed  Google Scholar 

  35. Olson JJ, Paleologos NA, Gaspar LE et al (2010) The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol 96:115–142

    Article  PubMed  CAS  Google Scholar 

  36. Fink J, Born D, Chamberlain MC (2011) Pseudoprogression: relevance with respect to treatment of high-grade gliomas. Curr Treat Options Oncol 12:240–252

    Article  PubMed  Google Scholar 

  37. Sanghera P, Perry J, Sahgal A et al (2010) Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37:36–42

    PubMed  Google Scholar 

Download references

Conflict of interest

David Roberge MD, Luis Souhami MD and Marie-Andrée Fortin, have received research funding for the conduct of this clinical trial. David Roberge and Luis Souhami, have served on advisory boards for Schering/Merck. Jean-François Pouliot PhD, is employed by Merck––the manufacturer of the trial drug.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Montreal General Hospital, Montreal, QC, Canada

    David Roberge & Luis Souhami

  2. Departement de Radio-Oncologie, Hôpital Notre-Dame de Montreal, TS-33661560, rue Sherbrooke est, Montreal, QC, H2L 4M1, Canada

    David Roberge & Marie-Andrée Fortin

  3. Merck Canada, Kirkland, QC, Canada

    Jean-François Pouliot

Authors
  1. David Roberge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis Souhami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marie-Andrée Fortin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean-François Pouliot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Roberge.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roberge, D., Souhami, L., Fortin, MA. et al. Chemosensitized radiosurgery for recurrent brain metastases. J Neurooncol 110, 265–270 (2012). https://doi.org/10.1007/s11060-012-0965-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-012-0965-6

Keywords

Search

Navigation